Marksans Pharma Limited (MARKSANS) Fair Value & Analysis
Healthcare · IN · Market cap ₹121B
Fair value as of: Jul 3, 2026
From 26 valuation models · updated today
Share price +9.1% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹156.89 – ₹272.81 · fair‑value band ₹139.90 – ₹247.27 · the ₹264.45 price screens above the ₹200.67 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Marksans Pharma Limited (MARKSANS) currently trades at ₹264.45, while our model-based Fair Value estimate is ₹200.67 — implying the stock looks roughly 24.1% overvalued today. We read business quality at 60/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Marksans Pharma Limited generated revenue of ₹29.5B at a net margin of 14.2%. Revenue grew 20.8% year over year. It earns a return on equity of 15.2%. The balance sheet holds a net cash position of ₹6.5B. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
Marksans Pharma Limited, together with its subsidiaries, engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. The company offers products in the pain management, cardiovascular, central nervous system, anti-diabetic, gastrointestinal, analgesics, upper respiratory, ear care, skincare, anticancer, anti-ulcerative, anti-allergy, antiviral, dietary, cardiac, dermatology, antihistamines, anti-fungal, anti-viral, laxatives, and cold and cough therapeutic areas. Its product portfolio includes plain, enteric-coated, and film coated tablets; soft gelatin and hard capsules; oral liquids; and ointments, as well as creams and liquids. The company provides its products to supermarkets, high street retailers, pharmacy chains, and wholesalers. Marksans Pharma Limited was incorporated in 1992 and is headquartered in Mumbai, India.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Marksans Pharma Limited reported revenue of ₹29.5B in FY2026 versus ₹14.8B in FY2022, a compound +18.8%/yr. Reported net income was ₹4.2B in FY2026, compounding +22.7%/yr from FY2022.
Is MARKSANS fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Eli Lilly and Company LLY | $1,107 | $395.92 | -64% |
| Johnson & Johnson, JNJ | 4,128 MXN | 159.68 MXN | -96% |
| AbbVie Inc ABBV | $224.95 | $129.90 | -42% |
| Roche Holding ROGN | 7,050 MXN | 316.37 MXN | -96% |
| Merck & Co MRCK34 | R$76.74 | R$50.09 | -35% |
| AstraZeneca PLC A1ZN34 | R$150.60 | R$23.54 | -84% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Marksans Pharma Limited (MARKSANS) undervalued?
What is the fair value of MARKSANS?
What is the quality score of MARKSANS?
What is the revenue of Marksans Pharma Limited (MARKSANS)?
What is the net profit margin of MARKSANS?
Does Marksans Pharma Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.